Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia

BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer.

Plinabulin is a first-in-class differentiated immune and stem cell modulator. The complementary mechanisms actions of Plinabulin and G-CSFs can prevent chemotherapy-induced neutropenia.

U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for Plinabulin in Prevention of Chemotherapy-Induced Neutropenia (CIN).

Chemotherapy-Induced Neutropenia (CIN) a common side effect is generally observed in cancer patients who are under treatment. CIN mainly destroys a type of white blood cells in a patient’s body which is considered to be the first line of defense against infections. Neutrophil, a type of white blood cell assures the patients from protecting against infectious diseases. Moreover, patients having low concentration of neutrophils may easily lead to infections, hospitalisation and death.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024